On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).
Cannabis for Pain Relief: An Area Ripe for Research
Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.
Findings from a Clinical Trial of Dazodalibep for Sjögren’s Disease
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue and pain than patients who received placebo.
The ACR Launches Rheumatoid Arthritis Measures Toolkit
The new resource offers standardized outcome measures for providers who treat patients with RA, as well as training materials for medical staff to guide accurate and efficient data collection. It also includes video tutorials and sample workflows for different EHR systems.
Break Barriers: Engaging Diverse Participants in Clinical Trials for Patients with Lupus
Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.
RheumMadness 2023: The Results Are In
RheumMadness is an online tournament in which a bracket of teams, representing key learning concepts in rheumatology, compete against each other in a series of head-to-head matchups, much like basketball teams in the NCAA’s March Madness. The 2023 tournament theme was The All Star Season. Each team represented one all star article competing to be…
Case Report: Giant Cell Arteritis-Related Stroke
Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…
How to Optimize Treatment for Aging Patients with Rheumatic Conditions
As patients with rheumatic musculoskeletal disease age, the number of medications they take may increase (i.e., polypharmacy), which can result in unwanted side effects and serious adverse effects. Lee et al. offer considerations and insights into caring for aging patients in a polypharmacy situation to better meet their health and lifestyle needs.
Drinking Raises Risk of Hip Replacement Due to OA
Marchand et al. sought to examine the relationship between alcohol consumption and hip osteoarthritis (OA) in women. By analyzing data from the Nurses’ Health Study cohort in the U.S., the researchers concluded that an association may be observed between higher alcohol consumption and greater incidence of total hip replacement due to OA.
A Novel Study Compared the Effectiveness of Adalimumab with Tofacitinib in RA
Your patient with rheumatoid arthritis (RA) isn’t responding well enough to methotrexate, and you both agree it’s time to consider a biologic or targeted synthetic disease-modifying anti-rheumatic drug (DMARD). But which one should you choose? In a treat-to-target era, we’re fortunate to have a variety of RA therapies at our disposal. Clinical practice guidelines from…
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 349
- Next Page »